As the field of cell and gene therapy rapidly evolves, developers face complex challenges at every stage of their journey. CDMOs are essential partners, providing the technical expertise and resources necessary to navigate these hurdles effectively. As a proven CDMO partner, MilliporeSigma, with over three decades of experience in viral vector development and manufacturing, offers the scalability and reliability required to advance complex programs with confidence.
This presentation explores how we leverage our established production platforms, regulatory know-how, and operational flexibility to accelerate timelines and enable our clients to achieve their next milestone, ranging from earliest proof-of-concept to market access, and anywhere in between. Through case studies, we will highlight our AAV and LV production platforms, showcasing successful client projects that demonstrate our capability to navigate the complexities of CGT development. Join us to learn how strategic CDMO support drives success at every milestone.